Compare NATR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NATR | GOSS |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.0M | 101.2M |
| IPO Year | 1995 | 2018 |
| Metric | NATR | GOSS |
|---|---|---|
| Price | $23.63 | $0.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $28.33 | $4.19 |
| AVG Volume (30 Days) | 122.8K | ★ 14.1M |
| Earning Date | 03-10-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.00 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $480,144,000.00 | $48,471,000.00 |
| Revenue This Year | $7.76 | N/A |
| Revenue Next Year | $3.82 | $147.82 |
| P/E Ratio | $22.30 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $11.01 | $0.32 |
| 52 Week High | $28.14 | $3.87 |
| Indicator | NATR | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 24.21 |
| Support Level | $23.14 | $0.33 |
| Resistance Level | $24.12 | $0.60 |
| Average True Range (ATR) | 1.28 | 0.04 |
| MACD | -0.13 | 0.06 |
| Stochastic Oscillator | 19.54 | 15.43 |
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.